Dramatic Responses of Recurrent Upper Urinary Tract Urothelial Carcinoma Harboring FGFR3 and TP53 Activating Mutations to Pembrolizumab in Combination with Erdafitinib: A Case Report

BACKGROUND: Upper tract urothelial carcinoma (UTUC) has a high recurrence rate and is likely refractory to systemic chemotherapy. The long-term outcomes and responses to immunotherapy and retreatment regimen after tumor recurrence for such cases had not yet been well-documented. CASE PRESENTATION: H...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Xinjia, Zong, Jianguo, Li, Xiang, Bai, Xiaoyan, Tan, Bowen, Sun, Weibing, Wang, Ruoyu, Ding, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006957/
https://www.ncbi.nlm.nih.gov/pubmed/33790580
http://dx.doi.org/10.2147/OTT.S297149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006957/
https://www.ncbi.nlm.nih.gov/pubmed/33790580
http://dx.doi.org/10.2147/OTT.S297149

Ejemplares similares